Retina · Cataract Surgery · Patient & Surgeon Series
The operation went well.
Then, weeks later,
the centre blurred.
Cystoid macular edema — Irvine-Gass syndrome — is the most common reason vision gets worse a month or two after an otherwise successful cataract operation. Inflammation makes the macula leak and fluid pools in tiny pockets inside the retina. Here is why it happens, who is at risk, how OCT catches it, and why most eyes recover.
CME after modern phaco
the typical onset window
by Irvine
Section 01 — What It Is
Not the new lens.
Not the old cataract.
A swollen macula.
When vision blurs again after cataract surgery, most people assume something is wrong with the implant. Usually it is not. One of the most common culprits in the first few months is cystoid macular edema (CME): swelling of the macula, the small central patch of retina responsible for reading, faces and fine detail.
Cataract surgery, however smooth, is a controlled injury to the front of the eye. The eye responds with inflammation, and inflammatory mediators — prostaglandins chief among them — diffuse backwards to the retina. There they loosen the tight junctions of the tiny perifoveal capillaries. Fluid seeps out and collects in the outer plexiform and inner nuclear layers, forming the characteristic cyst-like spaces arranged around the fovea like the petals of a flower.
The condition carries two names for historical reasons. Irvine described a vitreous syndrome after cataract surgery in 1953; Gass and Norton characterised its angiographic appearance in 1966. When it follows cataract surgery specifically it is called pseudophakic CME, or Irvine-Gass syndrome.
Cystoid macular edema after cataract surgery is swelling of the central retina caused by post-operative inflammation. Leaky capillaries around the fovea let fluid collect in small cyst-like spaces, which blurs and sometimes distorts central vision, typically four to twelve weeks after surgery. Symptomatic CME affects roughly 1–2% of eyes after modern uncomplicated phacoemulsification, more often in people with diabetes, uveitis, previous vein occlusion, an epiretinal membrane, or a complicated operation. OCT confirms it. Treatment usually starts with anti-inflammatory eye drops — an NSAID with a steroid — with injections reserved for persistent cases. Most eyes recover within months; a minority become chronic.
Section 02 — Interactive
Watch the macula
fill with fluid.
On OCT, CME has an unmistakable look: the normal dip of the foveal pit disappears, the central retina thickens, and dark, rounded cystic spaces appear around the centre. Drag the slider to increase the degree of post-operative leakage and see how the schematic retina changes.
The distinction the slider hints at matters clinically. Many eyes show a little extra macular thickening on OCT after surgery without any symptoms — so-called angiographic or subclinical CME — and this usually settles by itself. Clinical CME means the swelling is enough to reduce vision. That is the group treatment trials and incidence figures usually count.
Section 03 — Who Is at Risk
Most eyes never
get it. Some eyes
are primed for it.
The largest modern data set comes from a UK multicentre electronic-records study of about 82,000 eyes (Chu et al., 2016), which found an overall incidence of macular edema of roughly 1.2% within 90 days of surgery — and a clearly higher risk in eyes with certain pre-existing conditions or a complicated operation.
| Risk factor | Why it matters | What surgeons often do |
|---|---|---|
| Diabetes, especially with retinopathy | Retinal vessels are already fragile; surgical inflammation adds to existing leakage | Treat or stabilise diabetic macular edema before surgery; extra anti-inflammatory cover; OCT follow-up |
| Uveitis history | An eye prone to inflammation reacts more strongly to surgery | Aim for several months of quiet eye before operating; peri-operative steroid cover |
| Epiretinal membrane or previous vein occlusion | The macula is already structurally or vascularly compromised | Baseline OCT, closer monitoring, counselling about the higher risk |
| Posterior capsule rupture / vitreous loss | More inflammation; vitreous strands to the wound can exert traction | Careful anterior vitrectomy, intensified post-operative treatment |
| CME after surgery on the other eye | Suggests an individual predisposition | Prophylactic NSAID and closer review for the second eye |
Topical prostaglandin-analogue glaucoma drops have also been linked to CME in some reports, although the evidence is mixed. Some surgeons pause them around surgery in high-risk eyes; others do not. That decision belongs to the treating surgeon, and no one should stop glaucoma drops on their own.
Section 04 — Diagnosis
Good at week one.
Blurry at week six.
That timing is a clue.
The pattern is characteristic: a patient who read the chart well at the first post-operative visits returns a month or two later saying the new clarity has faded, straight lines look a little bent, or colours seem duller in the operated eye.
Optical coherence tomography (OCT) is now the standard test. It is quick and non-invasive, shows the cystic spaces and loss of the foveal contour directly, and gives a central thickness number that can be tracked over the course of treatment. Fluorescein angiography, the older gold standard, shows a classic petaloid pattern of dye pooling around the fovea and often leakage from the optic disc; it is still used when the cause of swelling is unclear — for instance, to separate pseudophakic CME from diabetic macular edema or uveitis.
Section 05 — Prevention & Evidence
What the largest
prevention trial showed.
Whether routine NSAID drops should be added to the standard post-operative steroid has been debated for years. The ESCRS PREMED study, a European multicentre randomised trial published in 2018, is the largest attempt to answer it.
In non-diabetic patients (Report 1), the combination of a topical NSAID (bromfenac) with a topical steroid (dexamethasone) was associated with a lower risk of clinically significant macular edema than either drop alone. In diabetic patients (Report 2), adding a subconjunctival triamcinolone injection at the end of surgery reduced macular thickening and edema, while an intravitreal anti-VEGF (bevacizumab) arm did not show a clear additional benefit in that trial. Practice still varies between surgeons and countries, but many now use combined NSAID and steroid prophylaxis at least in higher-risk eyes.
Illustrative visualisation of the direction and approximate relative magnitude reported across published studies and clinical references (see References). Bar lengths are rounded and qualitative, not pooled estimates from any single study; figures vary with definitions (clinical vs OCT), case mix and prophylaxis.
study (Chu et al., 2016)
analysed in that study
and diabetic patients
Section 06 — Treatment
Calm the inflammation.
Measure the macula.
Step up only if needed.
There is no single universal protocol, but treatment usually follows a stepwise logic guided by repeat OCT scans.
| Step | What it involves |
|---|---|
| 1. Topical therapy | An NSAID drop combined with a steroid drop, typically for several weeks, with OCT to confirm the swelling is falling. Many acute cases respond at this stage. |
| 2. Local steroid injection | For swelling that persists despite drops: a steroid injected beside the eye (sub-Tenon) or into the eye (intravitreal triamcinolone or a sustained-release dexamethasone implant). Eye pressure must be monitored, as steroids can raise it. |
| 3. Treat any mechanical cause | Vitreous strands to the wound, retained lens fragments or a malpositioned IOL rubbing the iris can keep inflammation going and may need surgical correction. |
| 4. Refractory options | Intravitreal anti-VEGF agents and other approaches have been used in selected chronic cases; evidence is more limited and decisions are individual. |
Section 07 — When to Act
Vision that fades
after surgery deserves
a scan, not new glasses.
CME is not usually an emergency, but it should be caught early: acute swelling responds better to treatment than swelling that has been present for many months.
A woman in her early seventies with well-controlled type 2 diabetes and mild background retinopathy has uneventful cataract surgery. At one week she reads the chart well and is delighted. Six weeks later she reports that print looks soft and slightly wavy in the operated eye. OCT shows loss of the foveal contour with cystic spaces around the fovea. She is started on a combined NSAID and steroid drop regimen and rescanned after a few weeks; the swelling is lower and her reading vision has improved, and it continues to recover gradually over the following weeks.
Seek same-day care instead if vision drops suddenly with increasing pain, redness or light sensitivity after surgery — that combination can signal infection (endophthalmitis) and is an emergency. A curtain or shadow in the side vision, or a sudden shower of floaters, needs urgent review for retinal detachment.
Section 08 — FAQ
Frequently asked questions
about CME after cataract surgery.
Cystoid macular edema (CME) after cataract surgery, also called pseudophakic CME or Irvine-Gass syndrome, is swelling of the macula, the central retina used for reading and fine detail. Inflammation triggered by surgery makes tiny retinal blood vessels leak, and fluid collects in small cyst-like spaces within the retina. It typically causes blurred or slightly distorted central vision that appears some weeks after an operation that initially went well.
Clinically significant CME most often appears roughly four to twelve weeks after surgery, commonly around six to eight weeks, which is why vision can seem good at the first check-ups and then become blurry later. It can occasionally appear earlier or, less commonly, months later, particularly in eyes with other risk factors.
Symptomatic CME after modern uncomplicated phacoemulsification is uncommon, reported in roughly 1 to 2 percent of eyes in large studies. A large UK database study of about 82,000 eyes found an incidence of about 1.2 percent within 90 days. Subclinical swelling that is visible only on OCT or angiography, without symptoms, is considerably more common.
Risk is higher in people with diabetes (especially with existing diabetic retinopathy), a history of uveitis, a previous retinal vein occlusion, an epiretinal membrane, or CME in the other eye after its surgery. A complicated operation, such as a posterior capsule rupture with vitreous loss, also raises risk. Surgeons may use extra anti-inflammatory treatment and closer monitoring in these eyes.
First-line treatment is usually topical anti-inflammatory eye drops, typically a non-steroidal anti-inflammatory drop (NSAID) combined with a steroid drop, used for several weeks. If the swelling persists, options include steroid injections around or inside the eye and, in selected refractory cases, other intravitreal treatments. Any contributing factor, such as vitreous caught in the wound, is addressed as well. Treatment is guided by OCT measurements.
Most cases of pseudophakic CME improve, many within a few months, either with treatment or on their own. A minority become chronic, lasting longer than several months, and these are harder to treat and more likely to leave some permanent reduction in sharpness. Prompt diagnosis with OCT and adherence to the prescribed drops give the best chance of full recovery.
References & Evidence Base
Peer-reviewed
citations.
Continue Reading
Related guides
from Beyond Vision.
Start writing here...
Cystoid Macular Edema After Cataract Surgery (Irvine-Gass Syndrome): Why Vision Blurs Weeks Later (2026 Guide)